KeytoLead

KeytoLead is formed by a team of world-class scientists with core competences within medicinal, computational, synthetic, and analytical chemistry. Both the founders and KeytoLead’s associates have a long track record of successful lead generation deliveries acquired from the pharmaceutical industry. Altogether, this team has been involved in more than 40 lead generation projects covering a vast diversity of target classes such as ion channels, proteases, polymerases, kinases, transporters, transferases and GPCRs.

Vast experience in Lead Generation

KeytoLead has expertise in all aspects of lead generation, such as compound selection, iterative screens, fragment based lead generation (FBLG), HTS evaluation (clustering, scoring and actives selection), development of clusters into lead series (expansion via compound libraries, scaffold hopping and multi-parameter optimisation), management of secondary screens (physical properties, ADMET), project management and presentation for customers or scientific committees.

Synthetic organic chemistry is an important area of lead generation which is why both single compound synthesis and compound library synthesis will be integrated parts of KeytoLead. The KeytoLead team has extensive experience in compound library generation from AstraZeneca’s Compound Collection Enhancement (CCE) initiative during the last 10 years. KeytoLead organic chemists are highly experienced and productive.

The power base to make it happen

KeytoLead scientists are highly skilled in predictive models including target modelling, virtual screening, high quality compound library design, compound triage and design, compound synthesis (including parallel synthesis) and automated purification. KeytoLead management team also has experience in leadership, line management, international collaborations, intellectual property and continuous improvement.